

10/634,709


2

PC25236A

AMENDMENTS TO THE ABSTRACT

Please replace the Abstract with the below amended abstract:

This invention provides compounds defined by Formula I



or a and pharmaceutically acceptable salt salts thereof,
wherein R¹, Q, S, T, U, V, and R² are as defined in the specification. The invention also
provides and pharmaceutical compositions comprising a compound of Formula I, or a
pharmaceutically acceptable salt thereof, as defined in the specification, together with a
pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides
methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the
animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The
invention also provides methods of treating a disease mediated by an MMP-13 enzyme in
a patient, comprising administering to the patient a compound of Formula I, or a
pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical
composition. The invention also provides methods of treating diseases such as heart
disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or
rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-
related macular degeneration, chronic obstructive pulmonary disease, asthma,
periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient,
comprising administering to the patient a compound of Formula I, or a pharmaceutically
acceptable salt thereof, either alone or in a pharmaceutical composition. The invention
also provides combinations, comprising a compound of Formula I, or a pharmaceutically
acceptable salt thereof, together with another pharmaceutically active component as
described in the specification.